Heimdall Insights

Global Rozanolixizumab Market

Sizing, Segmentation, & Growth Forecast (2025-2030)

Last updated: August 2026

Report Scope: The downloadable datasheet contains market sizes in USD for the period 2025-30.

Market Breakdown: Sizes and growth rates are broken down by geography and market segment (see below for details).

1. Summary

The Global Rozanolixizumab Market was valued at $550 mn. in 2025. During the forecast period 2025-2030, it is expected to grow at 18.5% CAGR, to an estimated market size of $1.3 bn. in 2030. A detailed breakdown by segment and geography is provided in the downloadable datasheet.

2. Market Definition

The market encompasses the global commercialization and therapeutic use of Rozanolixizumab (brand name Rystiggo), a humanized monoclonal antibody and neonatal Fc receptor (FcRn) antagonist. The scope primarily includes its application for generalized myasthenia gravis (gMG) in adults who are anti-AChR or anti-MuSK antibody-positive, while excluding non-specific immunosuppressive therapies and other non-FcRn targeted biologics.

3. Trends & Demand Drivers

Several key trends are expected to significantly impact the Rozanolixizumab Market in the period 2025-30:

4. Market Breakdown

The downloadable datasheet breaks market sizes and growth rates (CAGRs) down into the following geographies and segments:

Geographies

  • North America
  • Europe
  • Asia-Pacific
  • Rest of World

Segments

  • Generalized Myasthenia Gravis (gMG)
  • Other Indications (ITP, CIDP, MOGAD)